Gilead's $4.3 Billion Acquisition of CymaBay Signals Major Move in Liver Disease Treatment
TL;DR Summary
Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment, seladelpar, with potential blockbuster sales. The deal comes as Gilead seeks growth beyond its core HIV business and follows setbacks in clinical trials for other drugs. The acquisition is expected to complement Gilead's portfolio of liver disease treatments and is anticipated to be neutral to Gilead's earnings in 2025.
Topics:business#acquisition#business-pharmaceuticals#cymabay-therapeutics#gilead-sciences#liver-disease-treatment#seladelpar
- Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment CNBC
- CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal The Wall Street Journal
- Gilead Sciences will pay $4.3 billion for liver disease biotech CymaBay Therapeutics Axios
- CymaBay's stock surges as Gilead reaches $4.3 billion deal for liver-drug maker MarketWatch
- Gilead pays $4.3B for CymaBay's late-stage liver disease med FierceBiotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
75%
269 → 68 words
Want the full story? Read the original article
Read on CNBC